搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
1 天
5 Thyroid Myths Doctors Say to Stop Believing Now
Experts share thyroid myths to stop believing now. Mythbuster: While these symptoms can point to a thyroid issue, “weight ...
ophthalmologytimes
22 小时
Targeting IL-6 inflammation: A promising frontier in treating thyroid eye disease
Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 ...
emjreviews.com
6 天
Thyroid Diseases Increase Cancer and Osteoporosis Risks in Sjögren’s Syndrome
Thyroid diseases in primary Sjögren’s syndrome patients increase risks of malignancy and osteoporosis, driven by immune ...
7 天
on MSN
Understanding your thyroid, the master of metabolism
In this latest Texas Tech HSC expert column, Dr. Mohamad Sidani looks at the importance of thyroid health on the metabolism.
10 天
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen
Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the ...
Optics
8 天
ICFO near-IR platform sees details of thyroid pathologies
ICFO has now used the LUCA platform to characterize the thyroid tissue with simultaneous anatomical measurements, the first ...
Knowridge
4 天
How to prevent thyroid diseases in the natural way
The thyroid is a small, butterfly-shaped gland in your neck that plays a big role in your overall health. It produces ...
7 天
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 ...
Viridian Therapeutics advances promising therapies for thyroid eye disease. See why VRDN stock stands to benefit from a ...
Monthly Prescribing Reference
10 天
Veligrotug Beneficial for Patients With Chronic Thyroid Eye Disease
Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.
ophthalmologytimes
8 天
Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for ...
THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈